Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback